{
    "code": "02021826",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02021826",
    "time": "2020-02-25 12:47:03",
    "許可證字號": "衛署藥輸字第021826號",
    "註銷狀態": "已註銷",
    "註銷日期": "105\/05\/31",
    "註銷理由": "許可證已逾有效期",
    "有效日期": "101\/07\/24",
    "發證日期": "86\/07\/24",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202182608",
    "中文品名": "鹽酸鹽注射劑１２．５公絲\/公撮",
    "英文品名": "DOBUTAMINE HYDORCHLORIDE INJECTION 12.5MG\/ML",
    "適應症": "增強心肌收縮力而適用於短期治療，器質性心臟病、心臟外科手術引起心肌收縮力抑制而導致之心臟代賞能力衰竭。",
    "劑型": "270注射劑",
    "包裝": "盒裝 小瓶",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "藥品分類": "",
    "主製造廠": {
        "限制項目": "02輸　入",
        "申請商名稱": "620102S342  新加坡商赫士睿股份有限公司台灣分公司",
        "申請商地址": "新北市淡水區中正東路2段177號",
        "主製造廠": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2404300210",
            "成分名稱": "DOBUTAMINE HCL",
            "含量描述": "12.5",
            "含量": "12.5000000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "9600028300",
            "成分名稱": "SODIUM METABISULFITE (SOD. PYROSULFITE)",
            "含量描述": "0.22",
            "含量": "0.2200000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "020218260001.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021826&Seq=001&Type=9"
        }
    ]
}